Recombinant Human Prostaglandin D2 receptor (PTGDR)

What is the Prostaglandin D2 receptor and what are its main subtypes?

The Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that bind and are activated by prostaglandin D2. Also known as PTGDR or DP receptors, they play important roles in various functions of the nervous system and inflammation. These receptors include two main subtypes:

• Prostaglandin D2 receptor 1 (DP1) - encoded by the PTGDR1 gene

• Prostaglandin D2 receptor 2 (DP2) - encoded by the PTGDR2 gene (also known as CRTH2)

The distinction between these subtypes is important as they have different signaling pathways, tissue distribution, and physiological functions, which significantly impacts experimental design and interpretation of results.

What is the genomic structure and protein characteristics of human PTGDR?

The PTGDR gene encoding the prostaglandin D2 receptor in humans is located on the long arm of chromosome 14 at position 14q22.1 and consists of four exons. Molecular cloning studies have revealed that the corresponding cDNA encodes a protein with 359 amino acids and a molecular mass of 40,276 daltons.

The receptor's structure features:

• Seven rhodopsin-like transmembrane domains characteristic of G protein-coupled receptors

• An extracellular NH2 terminus

• An intracellular COOH terminus

• Three possible sites for N-glycosylation at the Asn-10, Asn-90, and Asn-297 residues

• Multiple phosphorylation sites for Protein kinase C (two in the first and second cytoplasmic loops and six in the COOH terminus)

This detailed structural knowledge is essential for designing experiments targeting specific domains or post-translational modifications of the receptor.

How do the signal transduction pathways differ between PTGDR subtypes?

The signaling pathways of the two PTGDR subtypes operate through different G protein coupling mechanisms:

DP1 (PTGDR1) Signaling:
The PGD2 receptor signaling pathway begins with prostaglandin D2 binding to the extracellular ligand site. This activates the Gs alpha subunit, which subsequently activates adenylate cyclase located on the cell membrane. Adenylate cyclase catalyzes the conversion of ATP to cyclic AMP (cAMP), resulting in elevated levels of this second messenger, which then triggers downstream cellular responses .

DP2/CRTH2 (PTGDR2) Signaling:
In contrast, the recombinant human CRTH2 receptor couples to Gi/o proteins, leading to a decrease in intracellular cAMP in a pertussis toxin-sensitive manner when activated by PGD2. This opposing effect on cAMP levels represents a fundamental difference in signaling mechanisms between the two receptor subtypes .

Understanding these distinct signaling pathways is crucial when designing pharmacological interventions or studying receptor-specific functions.

What tissues express PTGDR and how is this distribution significant for research?

PTGDR shows wide tissue distribution beyond the expected hematopoietic cells. Northern blot analysis has demonstrated PTGDR expression in:

• Brain

• Heart

• Thymus

• Spleen

• Various tissues of the digestive system

• Human eosinophils (confirmed by in situ hybridization)

Additionally, two eosinophilic cell lines (butyric acid-differentiated HL-60 and AML 14.3D10) endogenously express CRTH2. This widespread distribution suggests diverse physiological roles beyond inflammation and allergy, potentially including nervous system function, cardiac regulation, and digestive processes .

When designing experiments, researchers should consider this broad expression pattern, especially when studying tissue-specific functions or when using PTGDR as a potential therapeutic target.

How can PTGDR expression levels be reliably measured in clinical and research samples?

For accurate measurement of PTGDR expression levels, quantitative PCR (qPCR) following MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines is recommended.

Methodological approach:

• Extract RNA from whole blood or tissue samples

• Perform reverse transcription to generate cDNA

• Amplify PTGDR using validated primers (e.g., 5'-GGCATGAGGCCTAAAAATGAG-3' and 5'-CCTTGACATCCTTAAATGCTCC-3' for an 82-bp PTGDR fragment)

• Normalize expression data to at least two housekeeping genes (e.g., GAPDH and TBP)

• Verify primer efficiency and specificity

• Confirm correlation between reference genes (e.g., Spearman ρ analysis)

This methodology has demonstrated significant differences in PTGDR expression between allergic patients and healthy controls, with a sensitivity of 81.4% compared to 67% for IgE levels, indicating its potential value as a biomarker .

What are the binding characteristics of PGD2 and related compounds to PTGDR subtypes?

Radioligand binding studies with recombinant human PTGDR have revealed complex binding properties:

Binding sites:

• High affinity site: KD = 2.5 nM

• Low affinity site: KD = 109 nM

Ligand selectivity for CRTH2 (DP2):
PGD2 and related metabolites bind with the following rank order of potency:

• PGD2 > 13,14-dihydro-15-keto PGD2 > 15-deoxy-Δ12,14-PGJ2 > PGJ2 > Δ12-PGJ2 > 15(S)-15 methyl-PGD2

Ligand selectivity for DP1:
In contrast, DP1 shows a different binding profile:

• PGD2 > PGJ2 > Δ12-PGJ2 > 15-deoxy-Δ12,14-PGJ2 >>> 13,14-dihydro-15-keto-PGD2

This differential binding profile has significant implications for selective targeting of either receptor subtype in research and potential therapeutic applications. When designing experiments involving PTGDR ligands, researchers should carefully select compounds based on their receptor subtype selectivity.

How should researchers design receptor binding assays for PTGDR?

For robust PTGDR binding assays, consider the following methodological approach:

• Expression system selection:

  • HEK293(EBNA) cells have been successfully used for recombinant PTGDR expression

  • Alternatively, consider using eosinophilic cell lines that endogenously express CRTH2 (e.g., butyric acid-differentiated HL-60 or AML 14.3D10)

• Radioligand selection:

  • Tritiated PGD2 is commonly used with appropriate specific activity

  • Consider cold competition assays with unlabeled ligands to determine relative binding affinities

• Binding assay conditions:

  • Perform saturation binding to determine KD and Bmax values

  • Use equilibrium competition binding to determine Ki values for test compounds

  • Account for potential biphasic binding curves due to high and low affinity sites

• Data analysis:

  • Apply appropriate mathematical models (one-site, two-site binding)

  • Calculate equilibrium dissociation constants (KD) and inhibition constants (Ki)

This methodological approach has successfully characterized the binding properties of multiple PGD2 metabolites to recombinant PTGDR .

Which PTGDR polymorphisms are most relevant to allergy research and how should they be genotyped?

Several promoter polymorphisms of PTGDR have been implicated in allergic diseases:

Key polymorphisms:

• –1289G>A

• –1122T>C

• –881C>T

• –834C>T

• –613C>T

• –549T>C

• –441C>T

• –197T>C

• –95G>T

Of these, –1289G>A and –1122T>C show the strongest association with allergic conditions (P=.009). These polymorphisms are in strong linkage disequilibrium (coefficient=1, r²=0.985) .

Recommended genotyping methodology:

• Extract DNA from whole blood using automated systems (e.g., MagNA Pure Compact System)

• Amplify the PTGDR promoter region (1416-bp fragment) by PCR

• Sequence the amplified fragments

• Analyze genotype distributions and test for Hardy-Weinberg equilibrium

• Perform haplotype analysis when appropriate

Researchers should particularly focus on –1289G>A and –1122T>C polymorphisms when investigating genetic associations with allergic diseases.

How do PTGDR polymorphisms affect receptor expression and function?

The relationship between PTGDR polymorphisms and receptor expression provides insight into the functional consequences of genetic variation:

Expression effects:
The mutant homozygous genotypes AA and CC of polymorphisms –1289G>A and –1122T>C, respectively, are associated with statistically significantly lower PTGDR expression levels (P=.034) .

This finding suggests these polymorphisms affect transcriptional regulation of the PTGDR gene, potentially through altered binding of transcription factors to the promoter region.

Functional implications:

• Lower PTGDR expression may alter the sensitivity to PGD2 signaling

• Changes in receptor levels could impact inflammatory and allergic responses

• Polymorphism-associated expression differences may contribute to individual variability in disease susceptibility and treatment response

Researchers investigating PTGDR in allergic conditions should consider genotyping these key polymorphisms and correlating them with expression levels and clinical phenotypes.

How can PTGDR function be studied in cellular and animal models?

Cellular models:

• Recombinant expression systems:

  • HEK293(EBNA) cells expressing human CRTH2 have been established for pharmacological studies

  • These systems allow for controlled expression levels and mutational analysis

• Endogenous expression models:

  • Eosinophilic cell lines (butyric acid-differentiated HL-60, AML 14.3D10)

  • Primary human eosinophils (where CRTH2 mRNA expression has been confirmed)

Animal models:
DP receptor-deficient mice have provided valuable insights into PTGDR function in allergic asthma, demonstrating the involvement of the receptor in this condition .

Functional assays:

• Signal transduction:

  • Measurement of cAMP levels (increased for DP1, decreased for DP2/CRTH2)

  • G-protein coupling (Gs for DP1, Gi/o for DP2/CRTH2)

  • Pertussis toxin sensitivity (for DP2/CRTH2)

• Cell migration:

  • Chemotaxis assays to assess CRTH2-mediated cell migration in response to PGD2

  • Particularly relevant for studying eosinophil and Th2 lymphocyte recruitment

• Inflammatory responses:

  • Measurement of cytokine production

  • Assessment of cellular infiltration in tissues

These methodological approaches provide a comprehensive framework for investigating PTGDR function across different experimental systems.

What are the experimental considerations when studying PTGDR as a therapeutic target?

When investigating PTGDR as a therapeutic target, researchers should consider:

Receptor specificity:

• Clear distinction between DP1 and DP2/CRTH2 receptors is crucial

• Compounds may interact with both receptors with different affinities

• For example, nabilone targets both receptors with only slightly higher affinity for one, which may complicate data interpretation

Experimental design considerations:

• Compound selectivity verification:

  • Evaluate binding affinities for both receptor subtypes

  • Confirm functional selectivity through appropriate signal transduction assays

• Off-target effects:

  • Assess compound interaction with other prostaglandin receptors

  • Evaluate potential non-specific effects on other GPCRs

• In vivo validation:

  • Use receptor knockout models to confirm target specificity

  • Consider compensatory mechanisms in chronic administration studies

• Translational relevance:

  • Correlate findings with human genetic and expression data

  • Consider polymorphism-associated variability in drug response

Therapeutic potential context:
GPCRs represent important drug targets, with approximately 35% of approved drugs targeting these receptors . This highlights the potential of PTGDR as a therapeutic target, particularly in allergic and inflammatory conditions where its role has been established.

How can recombinant PTGDR be optimized for structural and functional studies?

Optimizing recombinant PTGDR for research applications requires consideration of several factors:

Expression system selection:

• Mammalian systems:

  • HEK293(EBNA) cells have been successfully used for functional PTGDR expression

  • CHO cells provide an alternative platform with potential for higher expression

  • Consider tetracycline-inducible systems for controlled expression levels

• Insect cell systems:

  • Baculovirus-infected Sf9 or High Five cells for higher protein yields

  • Suitable for structural studies requiring larger amounts of protein

Protein engineering strategies:

• Fusion tags:

  • N-terminal tags (His, FLAG) for purification and detection

  • Consider the impact of tags on receptor function and ligand binding

• Thermostabilizing mutations:

  • Introduction of specific mutations to enhance protein stability

  • Critical for crystallization and structural studies

• Domain swapping:

  • Creation of chimeric receptors to study domain-specific functions

  • Useful for mapping ligand binding sites and G-protein coupling domains

Functional validation:

• Confirm proper folding and trafficking to the plasma membrane

• Verify ligand binding properties using radioligand binding assays

• Assess G-protein coupling and downstream signaling

This methodological approach has been successful for structural and functional studies of other GPCRs and can be adapted for PTGDR research.

What are the latest techniques for studying PTGDR-mediated signaling in real-time?

Advanced methodologies for real-time assessment of PTGDR signaling include:

FRET/BRET-based approaches:

• cAMP monitoring:

  • EPAC-based FRET sensors for real-time cAMP measurements

  • Particularly useful for distinguishing DP1 (cAMP increase) from DP2 (cAMP decrease) signaling

• G-protein activation:

  • BRET-based assays measuring G-protein dissociation

  • Can distinguish between Gs (DP1) and Gi/o (DP2) coupling

Live-cell imaging techniques:

• Receptor trafficking:

  • GFP-tagged receptors for visualizing internalization and recycling

  • Particularly relevant for understanding desensitization mechanisms

• Calcium imaging:

  • Fluorescent calcium indicators for monitoring intracellular calcium flux

  • Important for secondary signaling events downstream of receptor activation

Single-molecule approaches:

• Single-molecule FRET to study conformational changes upon ligand binding

• Total internal reflection fluorescence (TIRF) microscopy for visualizing receptor dynamics at the membrane

Optogenetic tools:

• Light-activated control of receptor signaling

• Allows precise temporal and spatial control of receptor activation

These state-of-the-art methodologies enable detailed characterization of PTGDR signaling dynamics with unprecedented temporal and spatial resolution, providing deeper insights into receptor function.

How does PTGDR expression correlate with allergic phenotypes?

PTGDR expression shows significant correlation with allergic conditions:

Expression patterns in allergy:

• PTGDR expression levels are significantly higher in allergic patients compared to healthy controls (P<.001)

• This overexpression is observed across different allergic subgroups

Diagnostic value:

• Receiver operating characteristic analysis for PTGDR expression showed 81.4% sensitivity as a biomarker for allergy

• This compares favorably to IgE levels, which showed only 67% sensitivity

Expression-genotype relationships:

• The mutant homozygous genotypes AA and CC of polymorphisms –1289G>A and –1122T>C are associated with lower PTGDR expression (P=.034)

• These same polymorphisms show altered frequency in allergic patients (P=.009)

This data suggests PTGDR expression could serve as a valuable biomarker for allergic conditions, potentially with better performance than traditional markers like IgE. The correlation between specific genotypes and expression levels provides a mechanistic link between genetic variation and disease phenotype.

What methodological approaches can distinguish the roles of DP1 and DP2 in inflammatory responses?

To differentiate the roles of DP1 and DP2 in inflammation, consider these methodological approaches:

Pharmacological approaches:

• Selective agonists and antagonists:

  • DP1-selective compounds: BW245C (agonist), MK-0524 (antagonist)

  • DP2-selective compounds: 15(R)-15-methyl PGD2 (agonist), CAY10471 (antagonist)

• Metabolite profiling:

  • The metabolite 13,14-dihydro-15-keto PGD2 shows high affinity for DP2 but not DP1

  • This differential binding can be exploited to selectively activate DP2

Genetic approaches:

• Receptor-specific knockout models:

  • DP-deficient mice have demonstrated the role of DP1 in allergic asthma

  • Separate DP1 and DP2 knockout models allow isolation of receptor-specific effects

• siRNA-mediated knockdown:

  • Selective targeting of either receptor in cellular models

  • Useful for in vitro studies of inflammatory responses

Analytical techniques:

• Flow cytometry:

  • Assessment of receptor expression on specific immune cell populations

  • Correlation with activation markers and cytokine production

• Cell-specific responses:

  • DP2/CRTH2 mediates chemotaxis in T helper type 2 cells and eosinophils

  • DP1 has different effects on immune cell function

These methodological approaches provide a comprehensive toolkit for dissecting the distinct and sometimes opposing roles of DP1 and DP2 in inflammatory and allergic responses.